0.829
IF
20
MNiSW
166.26
ICV
REVIEW PAPER
 
CC BY-NC-ND 3.0
 
 

The role of Chromium III in the organism and its possible use in diabetes and obesity treatment

Sławomir Lewicki 1  ,  
Aneta Lewicka 2,  
 
1
Department of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Warsaw, Poland
2
Department of Hygiene and Physiology, Military Institute of Hygiene and Epidemiology, Warsaw, Poland
3
Division of Biochemistry, Department of Physiological Sciences, Faculty of Veterinary Medicine, University of Life Sciences (SGGW), Warsaw, Poland
4
Biological Threats Identification and Countermeasure Centre of the Military Institute of Hygiene and Epidemiology, Puławy, Poland
5
Emergency Medicine Unit, Medical University, Lublin, Poland
Ann Agric Environ Med 2014;21(2):331–335
KEYWORDS:
ABSTRACT:
Introduction:
Diabetes and obesity are diseases characterized by their increasing incidence every year. When comparing with healthy subjects, the serum levels of chromium (Cr) are lowered in these two diseases. Several studies conducted in laboratory animals with experimentally- induced diabetes demonstrated that supplementation with chromium ions (III) decreased glucose concentration in the blood, reduced the probability of atherosclerosis and heart attack, lowered the levels of cholesterol and low density lipoprotein (LDL). The Importance of chromium is actually challenged due to lack of clear manifestations of Cr deficiency in humans and animals.

Objective:
The aim of this review was to present current knowledge about Cr its role in the organism and possible mechanisms of its action also in metabolic disorders such as diabetes or obesity.

State of knowledge:
In the last decade, Cr was established to be rather a beneficial than essential trace element in mammals, and has gained popularity as a nutritional supplement and a component of many multivitamin/mineral formulations, fortified food and energy drinks. Cr supplements are widespread for diabetes and obesity treatment, despite conflicting reports on its efficacy. It was suggested that Cr shows a beneficial influence upon glucose and lipid disturbances.

Conclusions:
The recent clinical trials provided evidence both in favor and against the importance of Cr in healthy and ill organisms. Unfortunately, also the molecular mechanism by which chromium affects glucose and lipid metabolism is still unclear. Beneficial effects of diet supplementation with different sources of Cr 3+ can be potentially explained by rather pharmacological than nutritional effects.

CORRESPONDING AUTHOR:
Sławomir Lewicki   
Department of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Warsaw, Poland
 
REFERENCES:
1. Schwarz K, Mertz W. Chromium (III) and the glucose tolerance factor. Arch Biochem Biophys. 1959; 85: 292–295.
2. Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr. 1977; 30(4): 531–538.
3. Freund H, Atamian S, Fischer JE. Chromium deficiency during total parenteral nutrition. JAMA 1979; 241(5): 496–498.
4. Di Bona KR, Love S, Rhodes NR, McAdory D, Sinha SH, Kern N, et al.Chromium is not an essential element for mammals: effects of a “low-chromium” diet. J Biol Inorg Chem. 2011; 16(3): 381–390.
5. Weksler-Zangen S, Mizrahi T, Raz I, Mirsky N. Glucose tolerance factor extracted from yeast: oral insulin-mimetic and insulin-potentiating agent: in vivo and in vitro studies. Br J Nutr. 2012; 108(5): 875–882.
6. Dowling HJ, Offenbacher EG, Pi-Sunyer FX. Absorption of inorganic trivalent chromium from the vascular perfused rat small intestine. J Nutr. 1989; 119(8): 1138–1145.
7. EC (European Commission). Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Trivalent Chromium (expressed in 4 April 2003) http://ec.europa.eu/food/fs/sc/scf/out197_en.pdf (access: 2010.04.29).
8. Anderson RA, Bryden NA, Polansky MM, Gautschi K. Dietary chromium effects on tissue chromium concentrations and and chromium absorption in rats. J Trace Elem Exp Med. 1996; 9(1): 11–25.
9. Mertz W, Cornatzer WE, editors. Newer Trace Elements in Nutrition. New York, Marcel Dekker, 1971.
10. Ohh SJ, Lee JY. Dietary chromium-methionine chelate supplementation and animal performance. Asian-Aust. J Anim Sci.2005; 18(6): 898–907.
11. Wang MQ, He YD, Lindemann, MD, Jiang, ZG. Efficacy of Cr (III) supplementation on growth, carcass composition, blood metabolites, and endocrine parameters in finishing pigs. Asian-Aust. J Anim Sci. 2009; 22(10): 1414–1419.
12. Zha LY, Xu ZR, Wang MQ, Gu LY. Effects of chromium nanoparticle dosage on growth, body composition, serum hormones and tissue chromium in Sprague-Dawley rats. J Zhejiang Univ Sci B. 2007; 8(5): 323–330.
13. Chen NS, Tsai A, Dyer IA. Effect of chelating agents on chromium absorption in rats. J Nutr. 1973; 103(8): 1182–1186.
14. Davis ML, Seaborn CD, Stoecker BJ. Effects of over-the-counter drugs on 51 Chromium retention and urinary excretion in rats. Nutr Res. 1995; 15(2): 201–210.
15. Offenbacher EG. Promotion of chromium absorption by ascorbic acid. Trace Elem. Elect. 1994; 11, 178–181.
16. Samanta S, Haldar S, Ghosh TK. Production and carcase traits in broiler chickens given diets supplemented with inorganic trivalent chromium and an organic acid blend. Br Poultry Sci 2008; 49(2): 155–163.
17. Hill CH. Mineral interrelationships. In: Prasad AS, Oberleas D (eds.). Trace Elements in Human Health and Disease. New York, Academic Press, 1976.p.281–300.
18. Feng W, Li B, Liu J, Chai Z, Zhang P, Gao Y, et al. Study of chromium-containing proteins in subcellular fractions of rat liver by enriched stable isotopic tracer technique and gel filtration chromatography. Anal Bioanal Chem. 2003; 375(3): 363–368.
19. Clodfelder BJ, Vincent JB. The time-dependent transport of chromium in adult rats from the bloodstream to the urine. J Biol Inorg Chem. 2005; 10(4): 383–393.
20. National Research Council (US). Mineral Tolerance of Animals: Second Revised Edition. Washington, National Academies Press, 2005.
21. Feng WY, Ding WJ, Qian QF, Chai ZF. Study on the metabolism of physiological amounts of Cr(III) intragastrical administration in normal rats using activable enriched stable isotope Cr-50 compound as a tracer. J Radioanal Nucl Chem. 1988; 237(1–2): 15–19.
22. Feng W. The transport of chromium (III) in the body: Implications for function. In: Vincent JB, editor. The nutritional biochemistry of chromium (III). Amsterdam, Elsevier, 2007.p.121–137.
23. Borel JS, Anderson RA. Chromium. In: Frieden E (eds.). Biochemistry of the Essential Ultratrace Elements. New York, Plenum press, 1984. p.175–199.
24. Spears JW, Lloyd KE, Tiffany ME, Socha MT. Effect of supplemental chromium on tissue chromium concentrations in cattle. J Anim Sci. 2004; 82(1): 43.
25. Debski B, Gralak M, Bertrandt J, Kłos A. Wpływ karmienia z dodatkiem drożdży wzbogaconych chromem na stężenie cholesterolu, chromu, cynku i miedzi żółtkach jaj kurzych. Żywienie Człowieka i Metabolizm 2001; 28: 889–897 (in Polish).
26. Uyanik F, Eren M, Güçlü BK, Sahin N. Effects of dietary chromium supplementation on performance, carcass traits, serum metabolites, and tissue chromium levels of Japanese quails. Biol Trace Elem Res. 2005; 103(2): 187–197.
27. Ducros V. Chromium metabolism, a literature review. Biol Trace Elem Res. 1992; 32: 65–77.
28. Anderson RA, Bryden NA, Polansky MM, Richards MP. Chromium supplementation of turkeys: effects on tissue chromium. J Agric Food Chem. 1989; 37(1): 131–134.
29. Karagun BS, Temiz F, Ozer G, Yuksel B, Topaloglu AK, Mungan NO, et al. Chromium levels in healthy and newly diagnosed type 1 diabetic children. Pediatr Int. 2012; 54(6): 780–785.
30. Clodfelder BJ, Emamaullee J, Hepburn DD, Chakov NE, Nettles HS, Vincent JB. The trail of chromium(III) in vivo from the blood to the urine: the roles of transferrin and chromodulin. J Biol Inorg Chem. 2001; 6(5–6): 608–617.
31. WHO (World Health Organization) Trace elements in human nutrition and health. Geneva. 1996.
32. European Food Safety Authority (EFSA). Safety and efficacy of chromium methionine (Availa Cr) as feed additive for all species. EFSA J. 2009; 1043: 1–69.
33. Nielsen FH. Summary: The clinical and nutritional importance of chromium – Still debated after 50 years of research. In: Vincent JB, editor. The nutritional biochemistry of chromium (III). Amsterdam, Elsevier, 1995. p.265–276.
34. European Food Safety Authority (EFSA). Scientific Opinion on the safety of trivalent chromium as a nutrient added for nutritional purposes to foodstuffs for particular nutritional uses and foods intended for the general population (including food supplements). EFSA J 2010; 8(12): 1882.
35. Bennett R, Adams B, French A, Neggers Y, Vincent JB. High-dose chromium(III) supplementation has no effects on body mass and composition while altering plasma hormone and triglycerides concentrations. Biol Trace Elem Res. 2006; 113(1): 53–66.
36. Bunting LD, Tarifa TA, Crochet BT, Fernandez JM, Depew CL, Lovejoy JC. Effects of dietary inclusion of chromium propionate and calcium propionate on glucose disposal and gastrointestinal development in dairy calves. J Dairy Sci. 2000; 83(11): 2491–2498.
37. Lai MH, Chen YY, Cheng HH. Chromium yeast supplementation improves fasting plasma glucose and LDL-cholesterol in streptozotocin-induced diabetic rats. Int J Vitam Nutr Res. 2006; 76(6): 391–397.
38. McNamara JP, Valdez F. Adipose tissue metabolism and production responses to calcium propionate and chromium propionate. J Dairy Sci. 2005; 88(7): 2498–2507.
39. Lewicki S, Rattman D, Kuryl T, Snochowski M, Debski B. The effect of chromium (III) on fatty acid metabolism and insulin path related gene expression in mouse myocytes cell line C2C12. Żywność Nauka Technologia Jakość 2009; 16(4): 183–194.
40. Inanc N, Uyanik F, Sahin H, Yaman H, Erdem O. Effects of chromium supplementation on body composition, leptin, ghrelin levels and selected biochemical parameters in obese women Trace Elem Electrolytes 2006; 23(2): 128–133.
41. Lindemann MD. Use of chromium as an animal feed supplement. In: Vincent JB (eds.). The nutritional biochemistry of chromium(III). Amsterdam, Elsevier, 2007. p.85–118.
42. Ani M, Moshtaghie AA. The effect of chromium on parameters related to iron metabolism. Biol Trace Elem Res. 1992; 32: 57–64.
43. Schrauzer GN. Interactive effects of selenium and chromium on mammary tumor development and growth in MMTV-infected female mice and their relevance to human cancer. Biol Trace Elem Res. 2006; 109(3): 281–292.
44. Terpiłowska S, Siwicki AK. The role of selected microelements: selenium, zinc, chromium and iron in immune system. Cent Eur J Immunol. 2011; 36(4): 303–307.
45. Terpiłowska S, Siwicki, AK. The influence of chromium and iron on interleukin-1 alpha and interleukin-6 concentration in vitro and in vivo. Cent Eur J Immunol. 2011; 37(2): 106–109.
46. Burton JL, Nonnecke BJ, Dubeski PL, Elsasser TH, Mallard BA. Effects of supplemental chromium on production of cytokines by mitogen-stimulated bovine peripheral blood mononuclear cells. J Dairy Sci. 1996; 79(12): 2237–2246.
47. Lau FC, Bagchi M, Sen CK, Bagchi D. Nutrigenomic basis of beneficial effects of chromium(III) on obesity and diabetes. Mol Cell Biochem. 2008; 317(1–2): 1–10.
48. Yamamoto A, Wada O, Ono T. Distribution and chromium-binding capacity of a low-molecular-weight, chromium-binding substance in mice. J Inorg Biochem. 1984; 22(2): 91–102.
49. Wada O, Wu GY, Yamamoto A, Manabe S, Ono T Purification and chromium-excretory function of low-molecular-weight, chromium-binding substances from dog liver. Environ Res. 1983; 32(1): 228–239.
50. Davis CM, Vincent JB. Isolation and characterization of a biologically active chromium oligopeptide from bovine liver. Arch Biochem Biophys. 1997; 339(2): 335–343.
51. Yamamoto A, Wada O, Manabe S. Evidence that chromium is an essential factor for biological activity of low-molecular-weight, chromium-binding substance. Biochem Biophys Res Commun. 1989; 163(1): 189–193.
52. Vincent JB. Mechanisms of chromium action: low-molecular-weight chromium-binding substance. J Am Coll Nutr. 1999; 18(1): 6–12.
53. Chen G, Liu P, Pattar GR, Tackett L, Bhonagiri P, Strawbridge AB, et. al. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol. 2006; 20(4): 857–870.
54. Chen Y, Watson HM, Gao J, Sinha SH, Cassady CJ, Vincent JB. Characterization of the organic component of low-molecular-weight chromium-binding substance and its binding of chromium. J Nutr. 2011; 141(7): 1225–1232.
55. Peterson RL, Banker KJ, Garcia TY, Works CF. Isolation of a novel chromium(III) binding protein from bovine liver tissue after chromium(VI) exposure. J Inorg Biochem. 2008; 102(4): 833–841.
56. Stearns DM. Multiple hypotheses for chromium(III) biochemistry: why the essentiality of chromium(III) is still questioned. In: Vincent JB, editor. The nutritional biochemistry of chromium(III). Amsterdam, Elsevier, 2007. p.57–70.
57. Balamurugan K, Rajaram R, Ramasami T, Narayanan S. Chromium(III)-induced apoptosis of lymphocytes: death decision by ROS and Src-family tyrosine kinases. Free Radic Biol Med. 2002; 33(12): 1622–1640.
58. Pattar GR, Tackett L, Liu P, Elmendorf JS. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res. 2006; 610(1–2): 93–100.
59. Raja NS, Sankaranarayanan K, Dhathathreyan A, Nair BU. Interaction of chromium(III) complexes with model lipid bilayers: implications on cellular uptake. Biochim Biophys Acta. 2011; 1808(1): 332–340.
60. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A. 2004; 101(7): 2076–2081.
61. Mumtaz MM, Tully DB, El-Masri HA, De Rosa CT. Gene induction studies and toxicity of chemical mixtures. Environ Health Perspect. 2002; 110(6): 947–956.
62. Choe SY, Kim SJ, Kim HG, Lee JH, Choi Y, Lee H, et. al. Evaluation of estrogenicity of major heavy metals. Sci Total Environ. 2003; 312(1–3): 15–21.
63. Lewicki S. Ocena wpływu jonów chromu (III) podawanych w formie chlorku lub pikolinianu na białka ścieżki przekaźnictwa insulinowego oraz receptory estrogenowe α i β. Warszawa, SGGW, 2010.
64. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009; 301(20): 2129–2140.
65. Air EL, Kissela BM. Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms. Diabetes Care. 2007; 30(12): 3131–3140.
66. Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol. 2006; 35(1): 93–99.
67. Chen Y, Quick WW, Yang W, Zhang Y, Baldwin A, Moran J, et al. Cost of gestational diabetes mellitus in the United States in 2007. Popul Health Manag. 2009; 12(3): 165–174.
68. Sundararaman PG, Sridhar GR, Sujatha V, Anita V. Serum chromium levels in gestational diabetes mellitus. Indian J Endocrinol Metab. 2012; 1: 70–73.
69. Wysocka E, Cymerys M, Mielcarz G, Bryl W, Dzięgielewska S, Torliński L. The way of serum chromium utilization may contribute to cardiovascular risk factors in centrally obese persons Arch Med Sci. 2011; 7(2): 257–263.
70. Kuryl T, Debski B, Martinik K. The effect of microelements supplementation on beta-oxidation activity in healthy and type 1 diabetic rats. Cent Eur J Public Health. 2008; 16(4): 205–208.
71. Ryan GJ, Wanko NS, Redman AR, Cook CB. Chromium as adjunctive treatment for type 2 diabetes. Ann Pharmacother. 2003; 37(6): 876–885.
72. Komorowski JR, Tuzcu M, Sahin N, Juturu V, Orhan C, Ulas M, et al. Chromium picolinate modulates serotonergic properties and carbohydrate metabolism in a rat model of diabetes. Biol Trace Elem Res. 2012; 149(1): 50–56.
73. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care. 2004; 27(11): 2741–2751.
74. Hutchinson DS, Bengtsson T. α1A-Adrenoceptors Activate Glucose Uptake in L6 Muscle Cells through a Phospholipase C-, Phosphatidylinositol-3 Kinase-, and Atypical Protein Kinase C-Dependent Pathway. Endocrinol. 2005; 146(2): 901–912.
75. Wang ZQ, Zhang XH, Russell JC, Hulver M, Cefalu WT. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr. 2006; 136(2): 415–420.
76. Racek J, Trefil L, Rajdl D, Mudrová V, Hunter D, Senft V. Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus. Biol Trace Elem Res. 2006; 109(3): 215–230.
77. Cefalu WT, Rood J, Pinsonat P, Qin J, Sereda O, Levitan L, et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism. 2010; 59(5): 755–762.
78. Sharma S, Agrawal RP, Choudhary M, Jain S, Goyal S, Agarwal V. Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes. J Trace Elem Med Biol. 2011; 25(3): 149–153.
79. Drake TC, Rudser KD, Seaquist ER, Saeed A. Chromium infusion in hospitalized patients with severe insulin resistance: a retrospective analysis. Endocr Pract. 2012; 18(3): 394–398.
80. Surani SR, Ratnani I, Guntupalli B, Bopparaju S. Severe insulin resistance treatment with intravenous chromium in septic shock patient. World J Diabetes. 2012; 3(9): 170–173.
81. Jain SK, Kahlon G, Morehead L, Dhawan R, Lieblong B, Stapleton T, et al. Effect of chromium dinicocysteinate supplementation on circulating levels of insulin, TNF-α, oxidative stress, and insulin resistance in type 2 diabetic subjects: Randomized, double-blind, placebo-controlled study. Mol Nutr Food Res 2012; 56(8): 1333–1341.
82. Cefalu WT, Rood J, Pinsonat P, Qin J, Sereda O, Levitan L, et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism. 2010; 59(5): 755–761.
83. Lau FC, Bagchi M, Sen CK, Bagchi D. Nutrigenomic basis of beneficial effects of chromium(III) on obesity and diabetes. Mol Cell Biochem. 2008; 317(1–2): 1–11.
84. Tuzcu M, Sahin N, Orhan C, Agca CA, Akdemir F, Tuzcu Z, et al. Impact of chromium histidinate on high fat diet induced obesity in rats. Nutr Metab (Lond). 2011; 8: 28.
85. Iqbal N, Cardillo S, Volger S, Bloedon LT, Anderson RA, Boston R, et al. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord. 2009; 7(2): 143–150.
86. Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care. 2007; 30(8): 2154–2163.
87. Wang ZQ, Cefalu WT. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr Diab Rep. 2010; 10(2): 145–151.
88. Lukaski HC, Siders WA, Penland JG. Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. Nutrition. 2007; 23(3): 187–195.
89. Yazaki Y, Faridi Z, Ma Y, Ali A, Northrup V, Njike VY, et al. A pilot study of chromium picolinate for weight loss. J Altern Complement Med. 2010; 16(3): 291–299.
90. Nachtigal MC, Patterson RE, Stratton KL, Adams LA, Shattuck AL, White E. Dietary supplements and weight control in a middle-age population. J Altern Complement Med. 2005; 11(5): 909–915.
91. Masharani U, Gjerde C, McCoy S, Maddux BA, Hessler D, Goldfine ID, et al. Chromium supplementation in non-obese non-diabetic subjects is associated with decline in insulin sensitivity. BMC Endocr Disord 2012; 12: 31.
eISSN:1898-2263
ISSN:1232-1966